Amylyx Pharmaceuticals
↗Cambridge, USA
Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapies for high unmet medical needs, particularly in neurodegenerative diseases and endocrine conditions. The company is currently prioritizing its pipeline of investigational therapies, including avexitide for post-bariatric hypoglycemia (PBH) and other rare diseases.
Following the withdrawal of its ALS drug, Relyvrio/Albrioza, in 2024, the company has pivoted its strategic focus toward its late-stage clinical programs. Amylyx is headquartered in Cambridge, Massachusetts, and is publicly traded on the NASDAQ.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Neurodegenerative and Endocrine Therapeutics
SIZE & FINANCIALS
Employees:51-200
Founded:2013
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Investors:ALS Association, ALS Finding a Cure
STOCK
Exchange:NASDAQ
Ticker:AMLX
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3 (Avexitide)
Modalities:Small molecule, GLP-1 receptor antagonist, Antisense oligonucleotide
Active Trials:3
Trial Phases:Phase 1: 1 | Phase 2: 1 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Gubra A/S (Collaboration for GLP-1 receptor antagonist development)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Joshua Cohen - Co-CEO
Justin Klee - Co-CEO
Camille L. Bedrosian - Chief Medical Officer
Scientific Founders:Joshua Cohen, Justin Klee
Board Members:George Mclean Milne Jr., Daphne Quimi, Isaac Cheng, Paul Fonteyne, Karen Mindy Firestone, Bernhardt G. Zeiher
LINKS
Website:amylyx.com
LinkedIn:LinkedIn Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Amylyx Pharmaceuticals and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Amylyx Pharmaceuticals. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.